

## **Cancer Prevention and Control CIRB Meeting Agenda**

**May 28, 2020**

---

---

### **I. Continuing Review**

**A221602**, Olanzapine with or without fosaprepitant for the prevention of chemotherapy induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC): A Phase III Randomized, Double Blind, Placebo-Controlled Trial (Protocol Version Date 05/11/20)

---

---

### **II. Continuing Review**

**NRG-CC003**, Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with Or without Hippocampal Avoidance for Small Cell Lung Cancer (Protocol Version Date 02/14/19)

---

---

### **III. Continuing Review**

**NRG-CC004**, Phase II Double Blind Dose Finding Trial of Bupropion Versus Placebo for Sexual Desire In Women With Breast or Gynecologic Cancer (Protocol Version Date 06/07/19)

---

---

### **IV. Continuing Review**

**URCC-16092**, Phase II Study of Low-Dose Ibuprofen for Cognitive Problems in Patients with Cancer (Protocol Version Date 04/22/20)

---

---

### **V. Continuing Review**

**WF-30917CD**, A Stepped-Care Telehealth Approach to Treat Distress in Rural Cancer Survivors (Protocol Version Date 11/20/19)

---

---

### **VI. New Study ReReview**

**A191901**, Optimizing Endocrine Therapy Through Motivational Interviewing and Text Interventions (Protocol Version Date 05/12/20)

---

---